<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04699734</url>
  </required_header>
  <id_info>
    <org_study_id>BPN2020</org_study_id>
    <nct_id>NCT04699734</nct_id>
  </id_info>
  <brief_title>Peripheral Nerve Block in Patients With Painful Diabetic Polyneuropathy</brief_title>
  <official_title>Peripheral Nerve Block in Patients With Painful Diabetic Polyneuropathy: How Important is the Peripheral Signaling?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the present study is to evaluate the role of peripheral afferent input for&#xD;
      spontaneous pain in painful diabetic polyneuropathy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Both peripheral and central changes in the nervous system contribute to the development of&#xD;
      painful diabetic neuropathy, but how these changes contribute to the pain generation remains&#xD;
      yet to be fully understood.&#xD;
&#xD;
      The purpose of this study is to evaluate if a peripheral regional nerve block relieves&#xD;
      spontaneous pain in painful diabetic polyneuropathy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 8, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Indication of pain relieved extremity</measure>
    <time_frame>30 minutes</time_frame>
    <description>Number of participants who indicated the leg with lidocaine as most pain relieved 30 minutes after block And number of participants who indicated the leg with saline as most pain relieved 30 minutes after block</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain intensity</measure>
    <time_frame>90 minutes</time_frame>
    <description>Intensity of spontaneous pain (Numeric Rating Scale (NRS) 0-10, 0=no pain 10=worst pain imaginable) 30, 45, 60 and 90 minutes after block</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hyperalgesia and allodynia</measure>
    <time_frame>90 minutes</time_frame>
    <description>Intensity of hyperalgesia and allodynia from -5 to 5 (-5 = no sensation, 0=normal sensation, 5=extremely intense sensation) to brush, pinprick, cold and warm at baseline and if there is registered any signs of hyperexcitability at baseline then 35, 60 and 90 minutes after nerve block.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain relief</measure>
    <time_frame>45 minutes</time_frame>
    <description>Pain relief at 45 minutes after block assessed using a 6-point scale compared to pain intensity at baseline. (-1 = worse pain 0=no relief 1= little 2= moderate 3=good 4=complete)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain symptomps</measure>
    <time_frame>50 minutes</time_frame>
    <description>Intensity of neuropathic pain symptoms 50 minutes after nerve block Burning: NRS (0-10), 0=no burning 10=worst burning imaginable Squeezing: NRS (0-10), 0=no squeezing 10=worst squeezing imaginable Pressure: NRS (0-10), 0=no pressure 10=worst pressure imaginable Tingling: NRS (0-10), 0=no tingling 10=worst tingling imaginable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of evoked pain</measure>
    <time_frame>60 minutes</time_frame>
    <description>The distribution of any evoked pain to brush, pinprick, cold and warm before and 60 minutes after nerve block will be mapped using a filt pen and afterwards photographed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Painful Diabetic Neuropathy</condition>
  <condition>Neuropathic Pain</condition>
  <condition>Neuropathy;Peripheral</condition>
  <arm_group>
    <arm_group_label>Xylocaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nerve block</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Isotonic saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Nerve block</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Xylocaine 1%</intervention_name>
    <description>Nerve block</description>
    <arm_group_label>Xylocaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>NaCl 9mg/ml</intervention_name>
    <description>Nerve block</description>
    <arm_group_label>Isotonic saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 18 years or older.&#xD;
&#xD;
          -  Probably diabetic neuropathy confirmed using the Toronto criteria in a &quot;conservative&#xD;
             manner&quot;, i.e. three out of three symptoms/signs of neuropathy must be present (sensory&#xD;
             neuropathy symptoms, distal reduced sensibility, reduced ankle reflexes) 7.&#xD;
&#xD;
          -  Definite or probable neuropathic pain for minimum the last 6 months&#xD;
&#xD;
          -  Mean pain intensity at &gt; 4 NRS the last week17.&#xD;
&#xD;
        Since we expect a large effect of the block it is not necessary to discontinue pain&#xD;
        medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other causes of pain in the same area or other pain that cannot be distinguished from&#xD;
             the neuropathic pain.&#xD;
&#xD;
          -  Unable to understand and speak Danish.&#xD;
&#xD;
          -  Non-cooperative.&#xD;
&#xD;
          -  Warfarin or other medication that contraindicate regional anesthesia.&#xD;
&#xD;
          -  Infection in the injection area.&#xD;
&#xD;
          -  Allergy to lidocaine.&#xD;
&#xD;
          -  Pregnancy or lactating (fertile women must to show negative pregnancy test or use&#xD;
             anticonception).&#xD;
&#xD;
          -  Severe psychiatric disease e.g. severe depression during the last 6 months.&#xD;
&#xD;
          -  Alcohol or drug abuse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ellen L Schaldemose, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Danish Pain Research Center, Aarhus University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ellen L Schaldemose, MD</last_name>
    <phone>+45 93501942</phone>
    <email>ells@clin.au.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Danish Pain Research Center, Aarhus University, Aarhus University Hospital</name>
      <address>
        <city>Aarhus N</city>
        <state>Jutland</state>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ellen L Schaldemose, MD</last_name>
      <phone>93501942</phone>
      <email>ells@clin.au.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, Lauria G, Malik RA, Spallone V, Vinik A, Bernardi L, Valensi P; Toronto Diabetic Neuropathy Expert Group. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010 Oct;33(10):2285-93. doi: 10.2337/dc10-1303. Review. Erratum in: Diabetes Care. 2010 Dec;33(12):2725.</citation>
    <PMID>20876709</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>January 4, 2021</study_first_submitted>
  <study_first_submitted_qc>January 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2021</study_first_posted>
  <last_update_submitted>January 6, 2021</last_update_submitted>
  <last_update_submitted_qc>January 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
    <mesh_term>Polyneuropathies</mesh_term>
    <mesh_term>Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

